Expand all sections

Ixekizumab

Taltz

Extended indication

Ixekizumab monotherapy for treatment of active enthesitis-related or psoriatic juvenile idiopathic a

Therapeutic value

No estimate possible yet
Registration phase

Registration application pending

Product

Active substance

Ixekizumab
Domain

Chronic immune diseases
Reason of inclusion

Indication extension
Main indication

Rheumatism
Extended indication

Ixekizumab monotherapy for treatment of active enthesitis-related or psoriatic juvenile idiopathic arthritis in children and adolescents
Proprietary name

Taltz
Manufacturer

Eli Lilly
Mechanism of action

Interleukin inhibitor
Route of administration

Subcutaneous
Therapeutical formulation

Injection
Budgetting framework

Intermural (MSZ)

Registration

Registration route

Centralised (EMA)
Type of trajectory

Normal trajectory
ATMP

No
Submission date

August 2024
Expected Registration

June 2025
Orphan drug

No
Registration phase

Registration application pending
Additional remarks 
Verwachte registratie op basis van gemiddelde doorlooptijd van 10 maanden voor een indicatieuitbreiding.

Therapeutic value

Current treatment options

NSAIDs, glucocorticosteroiden, csDMARDS en TNFi (In-label adalimumab en etanercept en off-label golimumab)
Therapeutic value

No estimate possible yet
References 
NCT04527380 (I1F-MC-RHCG)

Expected patient volume per year

There is currently nothing known about the expected patient volume.

Expected cost per patient per year

Cost

9,902.61
References 
GIPdatabank (1)
Additional remarks 
In 2021 was de vergoeding per gebruiker van Taltz €9.902,61 (1). De verwachte kosten p.p.p.j. voor deze indicatie zal rond dit getal liggen.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.